Introduction: Children who develop any hypersensitivity reaction to eggs are routinely referred to hospital for Measles-Mumps-Rubella (MMR) vaccination as inpatients to prevent anaphylaxis. We aimed to study the association between hypersensitivity reactions after egg exposure and similar reactions after MMR immunisation; and examine the necessity of hospital admission for vaccination. Methods: A prospective observational study was conducted in Paediatric Department in Bukit Mertajam Hospital, Penang, between March and December 2014. Children referred from local polyclinics for inpatient MMR vaccination because of a history of egg allergy were recruited. The children were observed in the ward for post vaccination allergic reactions. Concurrently, a group of children without egg allergy was recruited from those admitted for other illnesses but had recent MMR vaccination at polyclinics. Parents of these children were interviewed and asked if they had observed any reactions post vaccination. In both groups, sociodemographics, medical history and family history of atopy were collected. Results: Eighty-seven subjects were recruited in this study. Fifty-four infants with egg allergy had previous mild allergic reactions after exposure to eggs or egg-related products. They were associated with a family history of egg hypersensitivity, personal history of acute gastroenteritis and upper respiratory tract infections. Two of them developed cutaneous rashes post vaccination during observation, but none developed anaphylactic or anaphylactoid reactions. Two infants among those without egg allergy had post vaccination fever. There was no association between egg allergy and hypersensitivity reactions to MMR vaccine (p=0.632). Conclusions: MMR vaccine can be safely administered to children with mild egg allergy, hence admission for vaccination in the hospital is not warranted. Risk stratification is required to ensure only infants with severe reactions will be admitted for vaccination.
Measles-Mumps-Rubella Vaccine

No abstract available.
Diploidy* ; Humans* ; Measles* ; Mumps* ; Rubella Vaccine* ; Rubella*

No abstract available.
Antibody Formation* ; Child* ; Diploidy* ; Humans* ; Immunization* ; Measles ; Measles-Mumps-Rubella Vaccine* ; Mumps ; Rubella ; Vaccination

BACKGROUND: Although several methods have been attempted in the treatment of warts, the traditional destructive method may be painful or ineffective and induce disfiguring scars. Therefore, a more tolerable method with fewer drawbacks is needed. OBJECTIVE: We studied the therapeutic effect of intralesional immunotherapy using the Measles, Mumps, and Rubella (MMR) vaccine and factors affecting it in patients with warts. METHODS: A retrospective study was performed in 207 patients with various types of warts, who did not meet the exclusion criteria for treatment and were followed-up from January 2011 to December 2013. Patients with warts were treated at 2-week intervals, and the therapeutic effect was evaluated 1 month after the final treatment. RESULTS: Overall, 123 (59.5%) patients experienced a greater than half reduction in the size and number of warts. In addition, younger patients (under the age of 20) (p=0.008) and those with common warts (including periungual warts) (p=0.02) showed significantly higher treatment responses. All patients complained of transient mild pain during the intralesional injections, but other side effects were rarely observed. Only 3.2% of patients who experienced a complete response had a recurrence more than 6 months after the final treatment. CONCLUSION: We suggest that intralesional immunotherapy with MMR vaccine can be considered as a primary remedy for patients who are sensitive to pain, especially children with multiple lesions, are concerned about serious side effects, or have common warts, and that treatment response will be improved by increasing the number of applications.
Child ; Cicatrix ; Humans ; Immunotherapy* ; Injections, Intralesional ; Measles* ; Measles-Mumps-Rubella Vaccine ; Mumps* ; Recurrence ; Retrospective Studies ; Rubella ; Rubella Vaccine* ; Warts*

OBJECTIVE: To investigate the epidemiological characteristics of mumps in mainland China from 2004 to 2018, and to provide data for the key population for prevention and control of mumps. METHODS: The epidemiological characteristics of mumps were analyzed with reference to the data of the cases of mumps reported in the National Scientific Data Sharing Platform for Population and Health and Disease Prevention and Control Bureau of National Health Commission of the People's Republic of China. Descriptive epidemiology was used to analyze the epidemiological characteristics of mumps. RESULTS: A total of 4 272 368 cases of mumps were reported in China during 2004-2018, with an average annual reported incidence rate of 21.44/100 000. A single dose of mumps-containing vaccine was added to the national Expanded Program of Immunization in 2008, but the annual incidence rate ranged from 12.84/100 000 to 35.59/100 000. The second dose of measles, mumps and rubella combined attenuated live vaccine was included in the routine immunization in Beijing, Tianjin and Shanghai, and then the average incidence rate of mumps reported in these three regions dropped to about 10/100 000. From 2004 to 2016, the population aged 3-14 years accounted for 81.16% of all patients with mumps. The children aged 6 years had the highest incidence rate of mumps during 2004-2013. CONCLUSIONS A single dose of mumps-containing vaccine has no obvious effect on the incidence rate of mumps. Children aged 6 years have the highest incidence rate of mumps. A booster dose of mumps-containing vaccine should be given to preschool children.
Adolescent ; Child ; Child, Preschool ; China ; Humans ; Measles ; Mumps ; Mumps Vaccine ; Rubella

BACKGROUND: Warts, caused by the human papilloma virus (HPV), are mucocutaneous proliferations controlled by cell-mediated immunity. Intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine, is postulated to induce a higher immune response for clearance of lesions.
OBJECTIVE: To assess the efficacy, safety and effect on recurrence of intralesional MMR vaccine for the treatment of warts.
METHODS: We searched online databases for randomized controlled trials on intralesional MMR vaccine for warts. Effects measured were the complete clearance of target and distant warts, adverse events noted and recurrence after treatment duration.
RESULTS: Four RCTs comparing intralesional MMR vaccine and placebo were assessed. Meta-analysis showed a risk ratio of 0.24 [95% CI: 0.18, 0.34] favoring intralesional MMR vaccine and a highly significant difference in completely clearing target warts (P-value <0.00001) versus placebo. Three of the 4 trials assessed response of distant warts showing a risk ratio of 0.28 [95% CI: 0.08, 0.96] and a significant difference (P=0.04) versus placebo. Pain and flu-like symptoms were the most common side effects with no recurrence seen after 3-6 months.
CONCLUSIONS: Intralesional MMR vaccine significantly reduces and clears target and distant warts as compared to placebo. It is a generally safe intervention with lasting effect assessed up to 6 months follow-up.

PURPOSE: With the implementation of measles vaccination programs, the number of patients with measles has decreased. However, epidemics still occur with high morbidity in infants less than 1 year of age. This fact calls for the establishment of optimal preventive measures against measles. The study was carried out to determine the effect of measles vaccination on an infant immunized before one year of age, any the measles immunity conferred by MMR. METHODS: Seventy-seven healthy infants (13.7 +/- 1.8 months) were immunized with the MMR vaccine (Triviraten Berna : Edmonston-Zagreb strain, Rubini strain, Wistar RA 27/3 strain), 50 of the infants have received measles vaccine before turning one-year old. The antibody titers of measles-specific IgG were measured by enzyme immunoassay. RESULTS: The antibody titers before and after MMR vaccination were significantly higher in infants previously immunized with measles vaccine compared to those not immunized. However, the greater number of infants not previously immunized with measles vaccine showed significant increase of measles antibody titers after MMR vaccination compared to those previously immunized with measles vaccine. Measles vaccine failure occurred in 6 infants (12.0%), all of whom acquired measles immunity following MMR vaccination. Measles immunogenicity to MMR did not differ with respect to the age of previous measles vaccination. CONCLUSION: The results indicate that measles vaccination in infants less than 1 year of age will not decrease the measles immunity following MMR vaccination, and it is suitable to vaccinate against measles in infants between 6-12 months of age, if needed.
Antibody Formation* ; Humans ; Immunization* ; Immunoenzyme Techniques ; Immunoglobulin G ; Infant ; Measles Vaccine ; Measles* ; Measles-Mumps-Rubella Vaccine ; Vaccination*

PURPOSE: With the implementation of measles vaccination programs, the number of patients with measles has decreased. However, epidemics still occur with high morbidity in infants less than 1 year of age. This fact calls for the establishment of optimal preventive measures against measles. The study was carried out to determine the effect of measles vaccination on an infant immunized before one year of age, any the measles immunity conferred by MMR. METHODS: Seventy-seven healthy infants (13.7 +/- 1.8 months) were immunized with the MMR vaccine (Triviraten Berna : Edmonston-Zagreb strain, Rubini strain, Wistar RA 27/3 strain), 50 of the infants have received measles vaccine before turning one-year old. The antibody titers of measles-specific IgG were measured by enzyme immunoassay. RESULTS: The antibody titers before and after MMR vaccination were significantly higher in infants previously immunized with measles vaccine compared to those not immunized. However, the greater number of infants not previously immunized with measles vaccine showed significant increase of measles antibody titers after MMR vaccination compared to those previously immunized with measles vaccine. Measles vaccine failure occurred in 6 infants (12.0%), all of whom acquired measles immunity following MMR vaccination. Measles immunogenicity to MMR did not differ with respect to the age of previous measles vaccination. CONCLUSION: The results indicate that measles vaccination in infants less than 1 year of age will not decrease the measles immunity following MMR vaccination, and it is suitable to vaccinate against measles in infants between 6-12 months of age, if needed.
Antibody Formation* ; Humans ; Immunization* ; Immunoenzyme Techniques ; Immunoglobulin G ; Infant ; Measles Vaccine ; Measles* ; Measles-Mumps-Rubella Vaccine ; Vaccination*

There has been continued controversy as to the safety of egg-based MMR vaccine in egg-allergic children. Many studies have dealt with MMR administrations to egg-allergic patients focusing on the systemic side reactions. It has been found that most egg-allergic patients do not react to MMR vaccine but to other vaccine components. Therefore, most authors conclude that if an individual can eat eggs without ill effects, he or she can take the MMR vaccine without skin testing. In this regard, this study describes two cases of systemic side reactions after injection of MMR vaccine to egg-allergic patients. In a case with a history of systemic reaction from egg ingestion, it is still recommended that skin testing with the vaccine be carried out. If the skin test result shows positive, incremental doses of the vaccine in every 15-20 minutes are suggested.
Child* ; Eating ; Egg Hypersensitivity* ; Eggs ; Humans ; Measles-Mumps-Rubella Vaccine* ; Ovum* ; Skin Tests

In this double-blind, randomized single-dose study, 194 healthy Filipino children aged 12-24 months were randomized into three groups (1:1:1) to receive one of the three lots of live-attenuated measles-mumps-rubella (MMR) vaccine to assess lot-to-lot consistency in safety and immunogenicity. Adverse events were recorded during 43-day post-vaccination follow-up period. Antibody levels were measured using ELISA pre-vaccination and on Day-60. No statistically significant differences were observed across groups for overall incidences of local and general symptoms (p>0.05) or immune response rates against the three antigens (p=0.835, 0.458 and 0.222 for anti-measles, anti-mumps and anti-rubella, respectively). The three lots demonstrated consistency in their reactogenicity and immunogenicity profile.
Human ; Male ; Female ; Infant ; MEASLES-MUMPS-RUBELLA VACCINE ; ENZYME-LINKED IMMUNOSORBENT ASSAY